TABLE 2

Pyrazole induces hepatic GST μ levels in vivo

Values represent fold increases in expression relative to untreated controls (n = 3). Means that are not significantly different are denoted by a common letter designation, whereas means with different letter designations are significantly different (p < 0.05) as determined by analysis of variance.

	GSTM1 mRNA	GST μ Protein	GST μ Activity (DCNB)
Dose* (mg/kg)
0	1 ± 0.1^a	1.0 ± 0.4^a	1.0 ± 0.1^a
50	4.3 ± 0.7^b	2.3 ± 0.4^b	2.0 ± 0.2^b
100	5.4 ± 1.0^b	3.3 ± 0.3^b,c	2.6 ± 0.2^b
200	4.8 ± 0.7^b	5.2 ± 1.2^c	2.3 ± 0.3^b
Time^† (h)
0	1.0 ± 0.0^a	1.0 ± 0.3^a	1.0 ± 0.1^a
12	1.9 ± 0.6^a	1.6 ± 0.5^a	0.8 ± 0.0^a
24	2.6 ± 0.1^a,b	2.1 ± 0.4^b	1.0 ± 0.0^a
48	4.4 ± 1.2^b,c	3.0 ± 0.3^b	1.6 ± 0.2^b
72	4.8 ± 0.7^c	5.2 ± 1.2^c	2.3 ± 0.3^c

↵* Mice were euthanized 72 h after treatment with the indicated doses of pyrazole.
↵† For time-course experiments, a dose of 200 mg/kg was used.